Global Allergy Immunotherapy Market Size By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy), By Application (Allergic Rhinitis, Allergic Asthma), By Region, And Segment Forecasts, 2023 to...

The Global Allergy Immunotherapy Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 4.7 billion by 2031, growing at a CAGR of 10.3% during the forecast period from 2023 to 2031. The rising prevalence of allergic conditions, increasing awareness about immunotherapy, and a shift from symptomatic treatments to disease-modifying therapies are key factors propelling market growth. Allergy immunotherapy, including subcutaneous and sublingual treatments, provides long-term relief and improved quality of life for patients suffering from allergic rhinitis, asthma, and venom allergies. As healthcare systems prioritize preventive and curative approaches, the market is witnessing growing adoption of personalized allergy treatment solutions.

Drivers:

1. Rising Incidence of Allergic Diseases:

The increasing global burden of allergic rhinitis, allergic asthma, and food allergies—driven by environmental pollution, dietary changes, and genetic predisposition—is generating significant demand for effective long-term treatment, including immunotherapy.

2. Growing Preference for Disease-Modifying Therapies:

Allergy immunotherapy addresses the root cause of allergies rather than merely managing symptoms. This transformative potential is prompting healthcare professionals to recommend immunotherapy as a preferred treatment strategy.

3. Advancements in Immunotherapy Formulations:

Improved delivery mechanisms, such as sublingual tablets and precision-formulated allergens, are enhancing patient compliance and efficacy, contributing to the market’s upward trajectory.

Restraints:

1. High Treatment Costs and Long Duration:

Despite its effectiveness, allergy immunotherapy involves prolonged treatment courses, often extending over 3 to 5 years, coupled with high costs, which can deter adoption in cost-sensitive healthcare markets.

2. Limited Access in Low-Income Regions:

A lack of allergists, inadequate infrastructure, and minimal awareness in developing regions hinder widespread adoption, limiting market penetration outside high-income countries.

Opportunity:

1. Expansion into Emerging Healthcare Markets:

The increasing awareness of chronic allergic conditions and the gradual improvement of healthcare infrastructure in Asia-Pacific and Latin America present substantial opportunities for market expansion.

2. Personalized and Recombinant Allergen Therapies:

Biotechnology advancements in personalized immunotherapy, including the use of recombinant allergens and biomarker-driven treatment protocols, are creating new revenue streams and clinical efficiencies.

Market by System Type Insights:

The Subcutaneous Immunotherapy (SCIT) segment held the dominant share in 2023 due to its widespread clinical acceptance and proven efficacy for respiratory allergies and venom hypersensitivity. However, the Sublingual Immunotherapy (SLIT) segment is anticipated to grow at the fastest pace, driven by ease of use, better patient adherence, and fewer systemic reactions compared to SCIT.

Market by End-use Insights:

The Homecare Settings segment is emerging as a fast-growing end-use category, propelled by patient demand for convenient and remote therapies. Still, Hospitals and Allergy Clinics retained the largest market share in 2023 due to the need for professional administration of SCIT and initial diagnostics.

Market by Regional Insights:

Europe led the global market in 2023, supported by high awareness, reimbursement structures, and robust allergy treatment infrastructure in countries like Germany, France, and the UK. However, the Asia-Pacific region is expected to exhibit the highest growth rate over the forecast period due to increasing allergic disease prevalence and expanding healthcare access in countries such as China, India, and Japan.

Competitive Scenario:

Prominent players in the global allergy immunotherapy market include ALK-Abelló A/S, Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, Leti Pharma, and Circassia Group. These companies are focusing on clinical trials, approvals of novel SLIT tablets, geographic expansion, and partnerships with healthcare providers to strengthen their global footprints.

Recent Key Developments:

In 2023, ALK-Abelló received EMA approval for its new SLIT tablet targeting house dust mite allergies.

Stallergenes Greer partnered with regional pharmaceutical firms in Southeast Asia in 2024 to expand distribution.

Allergy Therapeutics initiated Phase III trials for a next-generation grass pollen vaccine in 2025, targeting North American and European markets.

Scope of Work – Global Allergy Immunotherapy Market

FAQs:

1. What is the current market size of the Global Allergy Immunotherapy Market?

The market was valued at USD 2.1 billion in 2023.

2. What is the major growth driver of the Global Allergy Immunotherapy Market?

The primary driver is the rising incidence of allergic conditions and increasing adoption of long-term, disease-modifying therapies.

3. Which is the largest region during the forecast period in the Global Allergy Immunotherapy Market?

Europe dominated in 2023, but Asia-Pacific is expected to show the fastest growth through 2031.

4. Which segment accounted for the largest market share in the Global Allergy Immunotherapy Market?

The Subcutaneous Immunotherapy (SCIT) segment led the market in 2023 due to its established clinical efficacy.

5. Who are the key market players in the Global Allergy Immunotherapy Market?

Key players include ALK-Abelló A/S, Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, Leti Pharma, and Circassia Group.